Bayer Healthcare LLC

Bayer Healthcare LLC, operating through its Bayer Radiology division, supplies contrast media injectors, injection systems, preventative maintenance, and imaging informatics software to federal healthcare agencies as a prime contractor (100% of awards) competing entirely in full-and-open procurements with no set-aside participation. The company is a large for-profit pharmaceutical and medical device manufacturer headquartered in Whippany, New Jersey, competing across 41 distinct federal customer agencies.

Bayer's federal footprint centers on the Department of Veterans Affairs, which accounts for the overwhelming majority of its award volume and dollar concentration. The top five VA Veterans Integrated Service Networks drive 31% of total award count: VISN 4 leads with 110 awards ($3.5 million combined potential value), followed by VISN 10 (78 awards, $4.3 million), VISN 19 (55 awards, $13.3 million), VISN 5 (55 awards, $1.3 million), and VISN 9 (58 awards, $770 thousand). When measured by potential value, VISN 19 anchors the portfolio at $13.3 million across 55 awards, while VISN 23 ranks second at $4.6 million across 30 awards. The concentration signal is pronounced: these five VISNs represent 31% of award count but only 29% of combined potential value, indicating many small-dollar orders clustered at individual VA medical centers alongside fewer high-value system procurements. Beyond the VA, Bayer holds awards from the Defense Health Agency, National Institutes of Health Clinical Center, Indian Health Service, Air Combat Command, and other defense and civilian health agencies.

Bayer's capability portfolio derives almost entirely from its position as the original equipment manufacturer for MEDRAD contrast media injection systems and related imaging equipment. The company provides new equipment procurements, preventative maintenance agreements, emergency repair services, calibration and inspection work, software upgrades, and annual service plans for MEDRAD Stellant, Provis, Solaris, Arterion, and MRXperion injection systems used in computed tomography, magnetic resonance imaging, and positron emission tomography procedures. Representative prime contracts include a $682.667 million five-year definitive contract with VA Technology Acquisition Center for VISN 8 Radimetrics software (October 2025), a $480.821 million three-year Blanket Purchase Agreement with VISN 4 for MEDRAD sterilizer and injection system maintenance across nine Pennsylvania and Delaware medical centers (September 2025), a $228.436 million five-year definitive contract with VISN 22 for Bayer Radimetrics dose-monitoring software (March 2022), and a $418.092 million three-year Indefinite Delivery Contract with VISN 4 for MEDRAD preventative maintenance and repair services running through September 2025.

The award portfolio spans 1,142 total awards with combined potential value of $96 million and $77.8 million in obligated dollars (81% realization). Primary PSC and NAICS alignment reflects OEM device and maintenance posture: PSC J065 (Maintenance, Repair, and Rebuilding of Medical Equipment) accounts for 420 awards, and PSC 6545 (Medical and Surgical Instruments and Equipment) covers 373 awards. NAICS 811210 (Other Electronic and Precision Equipment Repair and Maintenance) dominates at 328 awards, followed by NAICS 339112 (Surgical and Medical Instrument Manufacturing) at 286 awards and NAICS 424340 (Medical, Dental, and Hospital Equipment Merchant Wholesalers) at 122 awards.

Activity has declined over the past five years, moving from 41 awards in 2022 to 18 in 2026 year-to-date. This contraction reflects both the completion of multi-year base contracts and the consolidation of fragmented VA single-site maintenance agreements into larger VISN-wide IDC and BPA vehicles—a structural change that reduces award count while maintaining or increasing transaction value per vehicle. Twenty-seven awards (combined potential value $1.9 million) face completion within the next twenty-four months, representing moderate recompete exposure concentrated in small-dollar maintenance call orders under existing VA vehicles.

Bayer competes as a sole-source provider on most MEDRAD work, justified under FAR 6.302-1 by its status as the only responsible source for proprietary equipment maintenance. The company holds no significant subcontractor relationships; its footprint consists entirely of prime awards. Parent vehicles center on VA IDCs and BPAs: the $418.092 million VISN 4 IDC (VA797P0257) carries 102 task orders totaling $14.6 million, the $480.821 million VISN 4 BPA (V552PBPA0629) carries 60 task orders at $2.9 million, and smaller regional IDCs with VISN 10, VISN 22, and other networks provide incremental maintenance call volume. The company does not hold positions on government-wide vehicles, GSA Schedule, or multi-agency IDIQs; its business is anchored entirely to VA regional service networks and direct awards from the Defense Health Agency and NIH.

Bayer's federal posture reflects classic OEM medical device dynamics: dominant market position in MEDRAD systems, sole-source maintenance justification that protects pricing and volume across fragmented VA procurement points, and limited exposure to competitive full-and-open bidding outside maintenance and consumables categories. Growth opportunities lie in software (Radimetrics footprint expansion across other VISNs) and equipment replacement cycles; near-term risk centers on VA consolidation of maintenance procurement into fewer, larger vehicles and potential competitive inroads from multivendor service aggregators in maintenance and repair categories.